2 recruiting, 1 terminated, 1 unknown, 1 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Metastatic Thyroid Cancer: new trials by email Literature Review of Metastatic Thyroid Cancer trials Research Report on Metastatic Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab, Tremelimumab - Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 79 | 2019-04-02 | 2026-03-11 |
| Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar] - Metastatic Thyroid Cancer | Phase 2 | Unknown | University Hospital, Essen | 70 | 2018-02-05 | 2023-06-22 |
| Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Cyclophosphamide, Sirolimus - Metastatic Thyroid Cancer | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 22 | 2017-04-27 | 2026-07-31 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer Aldesleukin, Fludarabine, Cyclophosphamide - Metastatic Thyroid Cancer | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2015-03-02 | 2019-12-16 |
Thyroid Neoplasms (5) · Adenocarcinoma, Follicular (2) · Thyroid Cancer, Papillary (2) · Neoplasm Metastasis (1)
Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Head and Neck Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Thyroid Diseases (5) · Adenocarcinoma (2) · Adenocarcinoma, Papillary (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cyclophosphamide (2) · Iodine-131 (1) · Sirolimus (1) · Thyrotropin Alfa (1) · aldesleukin (1) · dabrafenib (1) · durvalumab (1) · fludarabine (1) · selpercatinib (1) · trametinib (1) · tremelimumab (1)
Grupo Espanol de Tumores Neuroendocrinos (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · University Hospital, Essen (1) · University of Michigan Rogel Cancer Center (1)
United States (2) · Germany (1) · Spain (1)
James C Yang, M.D. (1) · Jaume Capdevila, M.D., Ph.D. (1) · Lori J. Wirth, MD (1) · Paul Swiecicki, M.D. (1) · Wolfgang P Fendler, MD (1)
2016 (1), 2018 (1)